The treatment of supraventricular arrhythmias.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000404:Ajmaline / Q000627:therapeutic use; D000638:Amiodarone / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001146:Arrhythmia, Sinus / Q000628:therapy; D001145:Arrhythmias, Cardiac / Q000628:therapy*; D001281:Atrial Fibrillation / Q000628:therapy; D001282:Atrial Flutter / Q000628:therapy; D002304:Cardiac Pacing, Artificial; D004077:Digoxin / Q000627:therapeutic use; D004206:Disopyramide / Q000627:therapeutic use; D004554:Electric Countershock; D006801:Humans; D010672:Phenytoin / Q000627:therapeutic use; D011342:Procainamide / Q000627:therapeutic use; D011802:Quinidine / Q000627:therapeutic use; D013610:Tachycardia / Q000628:therapy; D013614:Tachycardia, Paroxysmal / Q000628:therapy; D014700:Verapamil / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D000404:Ajmaline; D010672:Phenytoin; D004077:Digoxin; D014700:Verapamil; D004206:Disopyramide; D011802:Quinidine; D011342:Procainamide; D000638:Amiodarone